- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Total 50 results
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Sanjay Gandhi Postgraduate Institute of Medical...RecruitingBreast Cancer | Tumor Infiltrating Lymphocytes | Programmed Cell Death Ligand 1India
-
Nantes University HospitalUnknownBullous Pemphigoid | Immunotherapy | Programmed Cell Death Ligand 1France
-
Assiut UniversityUnknownProgrammed Cell Death 1Egypt
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Cancer Hospital; Sun Yat-sen University; Ningbo Medical Center Lihuili... and other collaboratorsRecruitingPlaque, Atherosclerotic | Programmed Cell Death Protein 1 InhibitorChina
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Tongji HospitalRecruitingHepatocellular Carcinoma | Effects of Immunotherapy | Programmed Cell Death 1China
-
Xiaorong DongUnknown
-
Sun Yat-sen UniversityNot yet recruitingCervical Cancer | Chemotherapy Effect | Neoadjuvant Therapy | Programmed Cell Death 1 Receptor / Antagonists & Inhibitors
-
Shanghai Jiao Tong University School of MedicineCompletedOral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive TherapyChina
-
Shanghai Jiao Tong University School of MedicineCompletedOral Cancer | VEGFR2 Inhibitor | Programmed Cell Death 1 Inhibitor | Inductive TherapyChina
-
China Medical University, ChinaNot yet recruitingPD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Immunotherapy | Survival Outcomes | Immune Checkpoint Inhibitors | Objective Response Rate | Metastatic Cervical Carcinoma | Tislelizumab | Persistent Cervical Carcinoma | Anti-programmed Cell Death Receptor 1China
-
Second Affiliated Hospital, School of Medicine,...RecruitingCarotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid ArteryChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
Sun Yat-sen UniversityRecruitingMuscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 InhibitorChina
-
Lei LiRecruitingCervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical CancerChina
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaboratorsRecruiting
-
University Hospital HeidelbergDepartment of Dermatology, Heidelberg University HospitalCompletedMelanoma | Exercise | PD-1 AntibodiesGermany
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Immune Checkpoint Inhibitors | Overall Survival | Anti-programmed Death-1 Antibody | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma | Objective Remission Rate | Progression-free Survival | Severe Adverse EventsChina
-
Shanghai Jiao Tong University School of MedicineRecruitingChemotherapy | Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant TherapyChina
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruiting
-
Shanghai Jiao Tong University School of MedicineRecruitingOral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFRChina
-
Nanfang Hospital of Southern Medical UniversityRecruitingEsophageal Squamous Cell Carcinoma | PD-1 InhibitorChina
-
Xuanwu Hospital, BeijingUnknownNon-small Cell Lung Cancer | PD-1 Antibody | Lung Cancer Stage II
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
The Affiliated Hospital of Qingdao UniversityUnknownNSCLC Stage IV | PD-1 | ARID1AChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Fuzhou General HospitalUnknownSmall Cell Lung Cancer | Lung Neoplasm | PD-1 InhibitorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingChemotherapy Effect | Lung Cancer Stage IV | PD-1 Antibody | Lung Cancer Squamous CellChina
-
Shandong New Time Pharmaceutical Co., LTDNot yet recruitingNSCLC | Non-small Cell Lung Cancer | PD-1China
-
Diwakar DavarMerck Sharp & Dohme LLC; Gateway for Cancer ResearchNot yet recruitingPD-1 Refractory Advanced MelanomaUnited States
-
Sichuan UniversityRecruitingNSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose RadiotherapyChina
-
Tang-Du HospitalRecruitingChemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | NeoadjuventChina
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Chest HospitalUnknownChemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
-
Fudan UniversityNot yet recruitingthe Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced MelanomaChina
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingEsophageal Squamous Cell Carcinoma (ESCC) | PD-1 InhibitorsChina
-
Fujian Cancer HospitalNot yet recruitingLung Adenocarcinoma | PD-1 Inhibitor | Stage IV Non-small Cell Lung Cancer | VEGF
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Yale UniversityMerck Sharp & Dohme LLCRecruitingPembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaMelanoma | Renal Cell Carcinoma | Metastatic Melanoma | Brain Metastases | Pembrolizumab | Lenvatinib | PD1/PD-L1 ExperiencedUnited States
-
Beijing Friendship HospitalNot yet recruitingLymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr VirusChina
-
Lei LiUnknownCamrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasChemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 AntibodyChina
-
Masonic Cancer Center, University of MinnesotaRecruitingCommon Variable Immunodeficiency | Chronic Granulomatous Disease | Hemophagocytic Lymphohistiocytosis | Wiskott-Aldrich Syndrome | X-linked Lymphoproliferative Disease | Langerhan's Cell Histiocytosis | Chediak-Higashi Syndrome | Griscelli Syndrome | Bare Lymphocyte Syndrome | SCID | Omenn's Syndrome | Reticular... and other conditionsUnited States